Related Experiment Videos
Cat-scratch disease
1Medical Emergency Services, Montefiore University Hospital, Pittsburgh, Pennsylvania.
Abstract:
Cat-scratch disease is a relatively common disorder that is the result of infection with a recently identified gram-negative bacillus. Although it is overwhelmingly a benign, self-limited illness requiring only supportive care, serious complications can occur and the disease may be life-threatening on occasion. Although randomized clinical trials of antibiotic therapy for CSD do not exist, CSD has demonstrated in vitro susceptibility to several antibiotics, and gentamicin has been reported beneficial in a few patients with systemic manifestations of the illness. Therefore, pending clinical trials, gentamicin may be worthy of consideration in CSD patients with serious manifestations of this illness. CSD is one of the most common causes of adenopathy and should be considered in all patients who present with unilateral or regional lymphadenopathy.
Insights
Cat-scratch disease (CSD) is a common bacterial infection causing swollen lymph nodes. While usually mild, severe cases may benefit from gentamicin treatment, pending further clinical trials.
Area of Science:
- Infectious Diseases
- Microbiology
- Immunology
Background:
- Cat-scratch disease (CSD) is a frequent cause of lymphadenopathy.
- It results from infection by a recently identified gram-negative bacillus.
- CSD is typically benign and self-limiting but can have severe complications.
Purpose of the Study:
- To review the clinical presentation and management of CSD.
- To evaluate the potential role of antibiotic therapy, specifically gentamicin, in severe CSD cases.
Main Methods:
- Review of existing literature on CSD.
- In vitro susceptibility data of the causative agent to antibiotics.
- Case reports of gentamicin use in systemic CSD.
Main Results:
- CSD is a common cause of unilateral or regional lymphadenopathy.
- The causative bacterium shows in vitro susceptibility to several antibiotics.
- Gentamicin has shown potential benefit in a limited number of patients with systemic CSD.
Conclusions:
- CSD should be considered in patients with lymphadenopathy.
- While supportive care is standard, gentamicin may be considered for severe CSD manifestations.
- Further clinical trials are needed to establish definitive antibiotic treatment guidelines for CSD.